Daily Endocrinology Research Analysis
Analyzed 59 papers and selected 3 impactful papers.
Summary
A multiscale, cross-species atlas functionally validated in >1,000 mouse models redefines the cellular drivers of skeletal disease and prioritizes new therapeutic targets. A multi-ancestry GWAS meta-analysis of thyroid cancer (16,167 cases) reveals 51 loci and pleiotropic mechanistic clusters enabling subtype-specific polygenic risk. A randomized crossover trial shows that premeal insulin lowers postprandial glycemia and increases myocardial microvascular blood flow in type 1 diabetes.
Research Themes
- Cellular atlases and functional genomics in skeletal (bone) disease
- Genetic architecture and pleiotropy in thyroid cancer across ancestries
- Therapeutic optimization: insulin timing and microvascular physiology in type 1 diabetes
Selected Articles
1. Multiscale analysis and functional validation of the cellular and genetic determinants of skeletal disease.
Using single-cell and cross-species genomics, the study maps 34 skeletal cell types, prioritizes disease-relevant populations via enrichment of rare disease and bone mineral density genes, and functionally validates targets in over 1,000 mouse models. It newly implicates endothelial and vascular smooth muscle cells in skeletal pathology and provides a framework to accelerate target discovery.
Impact: This resource-level work integrates human genetics with large-scale in vivo validation, redefining disease-relevant skeletal cell types and genes, and opening mechanistic avenues for bone-active therapeutics.
Clinical Implications: While preclinical, the atlas and validated gene sets prioritize targets (including vascular compartments) for osteoporosis and skeletal disorder drug development and may inform biomarker discovery.
Key Findings
- Identified 34 distinct skeletal cell types, defining a critical endosteal compartment regulating bone turnover.
- Prioritized disease-relevant cells using enrichment for rare skeletal disorder genes and BMD-associated loci from extended UK Biobank GWAS.
- Functionally validated hundreds of candidates in over 1,000 genetically modified mouse models.
- Revealed endothelial and vascular smooth muscle cells as previously underappreciated skeletal-disease-relevant populations.
Methodological Strengths
- Integration of single-cell, human GWAS enrichment, and large-scale in vivo functional validation (>1,000 mouse models).
- Cross-species approach increases mechanistic robustness and translational relevance.
Limitations
- Preclinical nature; translation from mouse to human pathophysiology may vary.
- Single-cell datasets and validations are focused on specific skeletal compartments and contexts.
Future Directions: Leverage the atlas to nominate and test vascular-targeted interventions in osteoporosis and integrate with longitudinal human imaging and serum biomarkers for clinical translation.
Musculoskeletal diseases are a major health burden. Development of bone-active therapies has been hindered by limited understanding of the cells and genes that regulate the skeleton. We exploited the value of cross-species analysis and developed single-cell methodologies in skeletal tissues to define the critical endosteal compartment that regulates bone turnover. Thirty-four distinct cell types were identified, and disease-relevant cells prioritized using enrichment for rare skeletal disorder genes and bone-mineral-density-associated genes in an extended UK Biobank genome-wide association study. Functional validation was undertaken in over 1,000 genetically modified mouse models. Endothelial cells and vascular smooth muscle cells were identified as new skeletal-disease-relevant cells alongside osteoblast, chondrocyte and osteoclast cell lineages. Hundreds of cell-specific genes with unappreciated roles in skeletal pathophysiology were identified. This comprehensive cellular and molecular framework underpins skeletal physiology and disease and will help prioritize new therapeutic targets to accelerate development of therapies to treat musculoskeletal disease.
2. Genetic drivers of etiologic heterogeneity in thyroid cancer.
A multi-ancestry GWAS meta-analysis (16,167 cases; 2.43M controls) identifies 51 loci (21 novel) and organizes risk into pleiotropic mechanistic clusters—thyroid function, oncogenic DNA repair/telomere pathways, and mixed physiology. Cluster-specific polygenic scores associate with thyroid and metabolic traits across ancestries, supporting genetically defined risk subtypes.
Impact: It extends thyroid cancer genetics with new loci and mechanistic clustering, enabling ancestry-spanning, subtype-specific polygenic risk and highlighting shared oncogenic pathways.
Clinical Implications: Clustered polygenic scores could refine risk stratification and screening, while implicating DNA repair/telomere pathways may guide prevention or targeted therapeutics.
Key Findings
- Identified 51 independent thyroid cancer risk loci (21 novel) from a multi-ancestry GWAS meta-analysis of 16,167 cases and 2,430,374 controls.
- Revealed pleiotropic mechanistic clusters: thyroid function/growth (TSH-enriched), oncogenic DNA repair/telomere (ATM, CHEK2, TP53, TERT), and mixed physiology.
- Cluster-specific polygenic scores associate with thyroid disease, cancer, and metabolic traits across diverse ancestries.
Methodological Strengths
- Large, multi-ancestry meta-analysis with over 2.4 million controls increases generalizability.
- Integration with 151 thyroid-related traits to derive interpretable mechanistic clusters and polygenic scores.
Limitations
- Heterogeneity in case ascertainment and genotyping across cohorts may introduce residual bias.
- Polygenic scores, while ancestry-spanning, may require calibration and clinical validation before implementation.
Future Directions: Prospective validation of cluster-specific polygenic scores in screening pathways and functional dissection of DNA repair/telomere mechanisms in thyroid tumorigenesis.
Thyroid cancer is the most common endocrine malignancy, yet its biological underpinnings remain incompletely understood. Here we show that common risk alleles for thyroid cancer point to distinct biological pathways underlying disease susceptibility. We perform a multi-ancestry genome-wide association meta-analysis of thyroid cancer (16,167 cases and 2,430,374 controls), identifying 51 independent loci, including 21 not previously reported. By integrating these loci with genetic associations for 151 thyroid-cancer-related traits, we identify pleiotropic mechanistic clusters linked to thyroid function, oncogenic pathways, and mixed physiological function. Two thyroid-specific clusters, associated with thyroid stimulating hormone or thyroid growth and function, are enriched in thyroid tissues. Oncogenic clusters include DNA repair (ATM, CHEK2, TP53) and telomere maintenance (TERT) genes, implicating shared cancer mechanisms. Cluster-specific polygenic scores are associated with thyroid disease, cancer, and metabolic traits across ancestry groups, suggesting distinct genetic subtypes of thyroid cancer risk and supporting pleiotropy-based approaches to genetic risk stratification.
3. Premeal insulin administration lowers postprandial blood glucose and increases myocardial microvascular blood flow in people with type 1 diabetes: a randomised, crossover clinical trial.
In a randomized crossover study of 18 adults with type 1 diabetes and 18 matched controls, premeal (vs postmeal) insulin significantly reduced postprandial glucose exposure and increased myocardial microvascular flow velocity and myocardial blood flow. Vital signs were unchanged, supporting a vascular benefit of appropriate prandial insulin timing.
Impact: This trial links a simple, scalable behavioral adjustment (premeal insulin timing) to acute improvements in cardiac microvascular perfusion, extending glycemic guidance to vascular endpoints.
Clinical Implications: Reinforces recommending premeal insulin dosing in type 1 diabetes to improve postprandial control and potentially support myocardial microvascular health.
Key Findings
- Premeal insulin significantly reduced postprandial glucose AUC vs postmeal dosing in type 1 diabetes (p=0.015).
- Premeal insulin increased myocardial microvascular flow velocity (p=0.031) and myocardial blood flow (p=0.044).
- No significant MBF changes were observed in other protocols; vital signs remained stable across conditions.
Methodological Strengths
- Randomized, crossover design controls for inter-individual variability.
- Objective cardiovascular physiological endpoints measured alongside glycemic outcomes.
Limitations
- Small sample size limits precision and generalizability.
- Short-term, surrogate endpoints; not powered for clinical cardiovascular outcomes.
Future Directions: Test varying pre-bolus intervals and delivery modes (MDI vs AID) on cardiac microvascular endpoints and long-term cardiovascular surrogates in larger trials.
AIMS/HYPOTHESIS: We aimed to evaluate whether prandial insulin timing affects vascular function in people with type 1 diabetes. Our hypothesis was that premeal insulin administration would lead to greater myocardial microvascular blood flow (MBF) via blunting postprandial hyperglycaemia. METHODS: People with type 1 diabetes between 18 and 35 years of age with BMI <30 kg/m RESULTS: Eighteen people with type 1 diabetes and 18 matched control participants were analysed within each protocol. Glucose area under the curve was significantly greater (p=0.015) in the postmeal insulin study compared with the premeal insulin study in participants with type 1 diabetes. Myocardial microvascular flow velocity significantly increased (p=0.031) with premeal insulin administration in people with type 1 diabetes and this consequently led to greater myocardial MBF (p=0.044). There were no changes in myocardial MBF within the other protocols. Changes in vital signs were similar between all protocols. CONCLUSIONS/INTERPRETATION: Appropriately timed premeal insulin led to lower postprandial blood glucose along with increased myocardial MBF in people with type 1 diabetes. Further work is needed to determine the underlying aetiology of these changes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04730882.